UNSPSC 51381905: Parecoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C19H18N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TUW81Y3CE, chemically known as propanamide, n-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)- but generally known as parecoxib, which bears US NIH Compound Identifier 119828. European Medicines Agency schedules Parecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03650MIG.

UNSPSC 51381905 Parecoxib is a Commodity code, but the recent state and local opportunities tagged under it do not involve parecoxib procurement itself. Instead, the code shows activity in pharmaceutical supply, naloxone distribution, and pharmacy benefit program management across multiple issuing bodies. State and local governments are soliciting pharmaceutical products and services through direct-to-manufacturer models, cooperative purchasing agreements, and emergency-response supply chains. The mix of issuing bodies includes county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). Vendors pursuing opportunities under this code should expect to navigate wholesaler-authorized distribution channels, cGMP and Drug Supply Chain Security Act compliance, and pricing models that may include rebate structures, net pricing, or WAC-minus formulations.

Recent activity centers on Florida and Minnesota, with a multi-state cooperative purchasing effort. Seminole County posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the contract includes a two-year initial term with one-year renewal option and potentially FEMA funding. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling upstream interest in direct contracting models outside traditional pharmacy benefit manager channels. MMCAP, administered by Minnesota's Department of Administration, posted an RFP (S1070000015802) on January 20, 2026, with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products spanning multiple states including Oregon; the contract requires vendors to partner with three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), comply with cGMP and DSCSA standards, and maintain $5,000,000 commercial general liability coverage with a two-year contract term effective July 1, 2026.